# XTL Biopharmaceuticals Ltd: financial statements, quarterly

XTLB · Nasdaq · CIK 1023549 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/xtlb.md) · [Financials](/companies/xtlb/financials.md) · [Filings](/companies/xtlb/filings.md) · [Insiders](/companies/xtlb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xtlb/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2014-12-31) | period not labelled (2015-12-31) | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-08-14) | FY2024 (2024-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [2,159](/filings/0001213900-18-003028.md) | [3,817](/filings/0001213900-19-003911.md) | [2,019](/filings/0001213900-20-006104.md) | [3,289](/filings/0001213900-21-027792.md) | [3,255](/filings/0001213900-22-016244.md) | [4,455](/filings/0001213900-23-021869.md) | [3,631](/filings/0001213900-23-021869.md) | [2,969](/filings/0001213900-25-037590.md) | [2,094](/filings/0001213900-25-037590.md) | [1,401](/filings/0001213900-25-037590.md) | not reported | [371](/filings/0001213900-25-037590.md) |
| Current assets | $k | not reported | not reported | [2,754](/filings/0001213900-18-003028.md) | [6,206](/filings/0001213900-19-003911.md) | [8,195](/filings/0001213900-20-006104.md) | [6,830](/filings/0001213900-21-027792.md) | [6,121](/filings/0001213900-22-016244.md) | [6,237](/filings/0001213900-23-021869.md) | [3,806](/filings/0001213900-23-021869.md) | [2,046](/filings/0001213900-25-037590.md) | not reported | [1,340](/filings/0001213900-25-037590.md) |
| Total assets | $k | not reported | not reported | [3,017](/filings/0001213900-18-003028.md) | [6,586](/filings/0001213900-19-003911.md) | [8,575](/filings/0001213900-20-006104.md) | [7,212](/filings/0001213900-21-027792.md) | [6,503](/filings/0001213900-22-016244.md) | [6,618](/filings/0001213900-23-021869.md) | [4,186](/filings/0001213900-23-021869.md) | [2,426](/filings/0001213900-25-037590.md) | [5,842](/filings/0001213900-25-037590.md) | [8,550](/filings/0001213900-25-037590.md) |
| Current liabilities | $k | not reported | not reported | [330](/filings/0001213900-18-003028.md) | [300](/filings/0001213900-18-003028.md) | not reported | not reported | not reported | not reported | not reported | [206](/filings/0001213900-25-037590.md) | not reported | [2,207](/filings/0001213900-25-037590.md) |
| Total liabilities | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [5,842](/filings/0001213900-25-037590.md) | not reported |
| Shareholders' equity | $k | [4,679](/filings/0001213900-18-003028.md) | [4,887](/filings/0001213900-19-003911.md) | [2,687](/filings/0001213900-20-006104.md) | [3,619](/filings/0001213900-21-027792.md) | [7,273](/filings/0001213900-22-016244.md) | [6,515](/filings/0001213900-23-021869.md) | [3,612](/filings/0001213900-23-021869.md) | [5,333](/filings/0001213900-25-037590.md) | [3,999](/filings/0001213900-25-037590.md) | [2,220](/filings/0001213900-25-037590.md) | not reported | [5,435](/filings/0001213900-25-037590.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 946,243,356 at 2025-12-31, from the cover of the [20-F filed 2026-06-30](/filings/0001213900-26-073831.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.